Category Archives: Blood Cancer Research

LLS’s mission in action: The 2013 Emerging Therapies & Survivorship Conference

This past Saturday’s Emerging Therapies & Survivorship Conference set a new record with nearly 700 patients, caregivers and health care professionals in attendance.  Survivorship was the theme of the day, starting with the warm welcome by Kathleen Leary, Chairperson of … Continue reading

Rate this:

Posted in Blood Cancer Research, General SF Chapter, Patient Services | Tagged , , | Leave a comment

To boldly go where no one has gone before

LLS’s mission (the Star Trek version): to explore new therapies, to champion survivorship and a new world without blood cancer and boldly go where no one has gone before. Not to be completely corny, but it’s true. Few nonprofits have … Continue reading

Rate this:

Posted in Blood Cancer Research, General SF Chapter | Leave a comment

Someday is Today

I am sure you have noticed, but our look has changed a bit. Truly Relentless, our chapter Facebook page, our chapter Twitter page and lls.org are more vibrant and highlight what we have been able to accomplish as an organization … Continue reading

Rate this:

Posted in Blood Cancer Research, General SF Chapter | Tagged | Leave a comment

Another CML win!

Like Pfizer’s Bosulif, newly approved Synribo (from Teva Pharmaceuticals) gives CML patients options. As I mentioned in my September post about Bosulif, CML patients have a specific type of genetic mutation called the Philadelphia chromosome. This mutation causes bone marrow to make an enzyme … Continue reading

Rate this:

Posted in Blood Cancer Research | Tagged , , | Leave a comment

Accelerating cures through venture philanthropy

Venture philanthropy. It’s a buzz phrase going around and gaining ground in the nonprofit arena. Early last month, LLS announced an exciting new venture philanthropy partnership with Celgene Corporation, the makers of Revlimid, a drug for multiple myeloma. So what are … Continue reading

Rate this:

Posted in Blood Cancer Research, LLS Partners | Tagged , | Leave a comment

Our MDS “white knight” moves forward to the finish!

We all like happy endings and this is the best kind! Just last week, rigosertib, a  myelodysplastic syndrome (MDS) drug with tremendous potential, received sizable funding – the kind that will get it across and beyond the finish line. It’s a great story, … Continue reading

Rate this:

Posted in Blood Cancer Research, General SF Chapter | Tagged , , , , , | Leave a comment

Cancer-fighting rabbits

An unusual (but great) research update for an unusual day – the second Friday the 13th of the year. If you didn’t already love rabbits for their soft fur and cute twitching noses, you may come to love them for their … Continue reading

Rate this:

Posted in Blood Cancer Research | Leave a comment

Wanabe like Gleevec

In 2001, a “magic little pill” called Gleevec changed cancer treatment forever and chronic myeloid leukemia became a managable chronic condition with minimal side effects. Now fast forward to present day; Gleevec has FDA approval for ten different cancers. Think of the number of … Continue reading

Rate this:

Posted in Blood Cancer Research, General SF Chapter, Man & Woman of the Year | Tagged , , , , , | Leave a comment

Zebrafish against cancer

What do zebrafish and people have in common? More than you might think actually. The zebrafish genome and immune system is similar to ours. So scientists can use them as models to identify molecules that kill leukemia cells. Last month researchers … Continue reading

Rate this:

Posted in Blood Cancer Research | Tagged , | Leave a comment

Finding a new therapy for MDS

Today there are just a handful of treatments for patients with myelodysplastic syndrome (MDS), a condition that involves ineffective blood cell production. Patients often develop severe anemias and require frequent blood transfusions. In the worst case scenario, MDS can evolve into … Continue reading

Rate this:

Posted in Blood Cancer Research, LLS Partners | Tagged , , , , , | Leave a comment